Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 14:45 ET | Source: Tevogen Bio Inc

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Tevogen clarifies GAAP-reported deficit, citing strong capital efficiency, low cash burn, and plans to share reconciled non-GAAP metrics.
November 03, 2025 08:00 ET | Source: Halberd Corp.

Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University

Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
November 03, 2025 07:59 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
November 03, 2025 07:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Frank Clyburn to Board of Directors

Kailera Therapeutics appoints 30-year biopharma industry veteran Frank Clyburn, Jr to its Board of Directors
November 03, 2025 07:00 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine...
October 31, 2025 16:30 ET | Source: Edesa Biotech, Inc.

Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
October 31, 2025 16:30 ET | Source: Cellectis Inc.

Cellectis to Report Third Quarter Financial Results on November 7, 2025

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
October 31, 2025 08:00 ET | Source: Aemetis, Inc.

Aemetis to Review Third Quarter 2025 Financial Results on November 6, 2025

Aemetis to Review Third Quarter 2025 Financial Results on November 6, 2025
October 30, 2025 20:30 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China

ICP-B794 has demonstrated superior anti-tumor activity in animal models, and exhibited significant tumor-killing effects even in large tumors.
October 30, 2025 08:30 ET | Source: ALX Oncology

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a...